Reporter Kim Seong-min of Biospectator
This article ‘Paid news service BioS+’ This is an article.
First published interim results of phase 2 clinical trial of ‘poseltinib’ combination therapy for PCNSL, confirmed safety and early anticancer activity… Expected to provide new treatment options based on inhibition of multiple phosphorylation mechanisms and BBB permeability mechanism
New drug development biotech NOBO Medicine announced on the 9th that it announced the interim results of the initial phase 2 clinical trial of triple combination therapy with the BTK/TEC inhibitor ‘poseltinib (NB02)’ for patients with relapsed or refractory primary central nervous system lymphoma (r/r PCNSL) at the American Society of Hematology (ASH 2025) held in Orlando, USA.
The POTENTIAL-P phase 2 clinical trial data released this time is based on safety lead-in cohort data and confirmed clinically manageable safety and early anti-tumor activity in a group of patients with relapsed or refractory PCNSL for which there is currently no appropriate treatment.
Poseltinib is a BTK inhibitor that was previously licensed out (L/O) by Hanmi Pharmaceutical to Eli Lilly in 2015 and returned after 4 years as a candidate for the treatment of autoimmune diseases. In 2021, Hanmi Pharmaceutical confirmed the possibility of developing it as an anticancer drug through joint research with Novo Medison (formerly Genome Opinion) to explore new indications. Afterwards, the possibility of development as a combination drug was confirmed in the phase 2 clinical trial for researchers targeting diffuse large B-cell lymphoma (DLBCL).
Novo Medison licensed (L/I) the worldwide rights to Poseltinib from Hanmi Pharmaceutical in June last year, and the terms of the contract were not disclosed at the time. Novomedison confirmed that poseltinib is a multi-kinase inhibitor that inhibits BTK, TEC, and BMX, has a broader inhibition mechanism than existing BTK inhibitors, and has a safety profile and potential to penetrate the blood-brain barrier (BBB)…
Additional information is only available to paid members.
If you are a member, please log in and click to register.
